<?xml version="1.0" encoding="UTF-8"?>
<p id="p0060">To ensure that COVID-19–related medical products are rapidly assessed as potential treatments or vaccines, health authorities have considered expedited pathways,
 <xref rid="bib3" ref-type="bibr">
  <sup>3</sup>
 </xref> either through an already-existing pathway or as a new COVID-19–related emergency pathway.
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref>
 <xref rid="tbl1" ref-type="table">Table I</xref> describes some examples of the various regulator-offered expedited pathways for COVID-19–related medical products.
</p>
